Search hospitals

>

Wisconsin

>

Milwaukee

Medical College of Wisconsin

Claim this profile

Milwaukee, Wisconsin 53226

Global Leader in Cancer

Global Leader in Lung Cancer

Conducts research for Multiple Myeloma

Conducts research for Breast Cancer

Conducts research for Pancreatic Cancer

1364 reported clinical trials

135 medical researchers

Photo of Medical College of Wisconsin in MilwaukeePhoto of Medical College of Wisconsin in MilwaukeePhoto of Medical College of Wisconsin in Milwaukee

Summary

Medical College of Wisconsin is a medical facility located in Milwaukee, Wisconsin. This center is recognized for care of Cancer, Lung Cancer, Multiple Myeloma, Breast Cancer, Pancreatic Cancer and other specialties. Medical College of Wisconsin is involved with conducting 1,364 clinical trials across 1,407 conditions. There are 135 research doctors associated with this hospital, such as Nirav Shah, MD, Binod Dhakal, MD, William Bradley, MD, and Meghen B. Browning.

Area of expertise

1

Cancer

Global Leader

Medical College of Wisconsin has run 108 trials for Cancer. Some of their research focus areas include:

Stage IV
Stage III
p16 positive
2

Lung Cancer

Global Leader

Medical College of Wisconsin has run 85 trials for Lung Cancer. Some of their research focus areas include:

Stage IV
Stage III
Stage II

Top PIs

Clinical Trials running at Medical College of Wisconsin

Lung Cancer

Skin Cancer

Prostate Cancer

Breast cancer

Breast Cancer

Kidney Cancer

Ovarian Cancer

Multiple Sclerosis

Pancreatic Cancer

Uterine Cancer

Image of trial facility.

Treatment Timing

for Non-Small Cell Lung Cancer

This phase III trial compares standard therapy given after surgery (adjuvant) to standard therapy given before and after surgery (perioperative) in treating patients with stage II-IIIB non-small cell lung cancer (NSCLC) that can be removed by surgery (resectable). The usual approach for patients with resectable NSCLC is chemotherapy and/or immunotherapy before surgery, after surgery, or both before and after surgery. This study is being done to find out which approach is better at treating patients with lung cancer. Treatment will be administered according to the current standard of care at the time of enrollment. Chemotherapy options may include cisplatin, carboplatin, pemetrexed, gemcitabine, docetaxel, and vinorelbine at standard doses according to the treating physician. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by stopping cells from using folic acid to make deoxyribonucleic acid (DNA) and may kill tumor cells. Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill tumor cells. Docetaxel is in a class of medications called taxanes. It stops tumor cells from growing and dividing and may kill them. Other chemotherapy drugs, such as vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading . Immunotherapy with monoclonal antibodies, such as nivolumab, pembrolizumab, and atezolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Starting treatment with chemotherapy and immunotherapy prior to surgery and continuing treatment after surgery may be a more effective treatment option than adjuvant therapy alone in patients with stage II-IIIB resectable NSCLC.

Recruiting

2 awards

Phase 3

4 criteria

Image of trial facility.

Radiation Therapy

for Brain Metastasis

This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. FSRS delivers a high dose of radiation to the tumor over 3 treatments. SRS is a type of external radiation therapy that uses special equipment to position the patient and precisely give a single large dose of radiation to a tumor. FSRS may be more effective compared to SRS in treating patients with cancer that has spread to the brain.

Recruiting

2 awards

Phase 3

12 criteria

Image of trial facility.

Immunotherapy + Chemotherapy

for Non-Small Cell Lung Cancer

This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.

Recruiting

2 awards

Phase 3

27 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Medical College of Wisconsin?

Where is Medical College of Wisconsin located?

Who should I call to ask about financial aid or insurance network?

What insurance does Medical College of Wisconsin accept?

What awards or recognition has Medical College of Wisconsin received?